Evidence map›Paper›PMID 37108634›Full record

ReviewInternational journal of molecular sciences2023

Human Endogenous Retrovirus, SARS-CoV-2, and HIV Promote PAH via Inflammation and Growth Stimulation.

Desheng Wang, Marta T Gomes, Yanfei Mo, Clare C Prohaska, Lu Zhang, Sarvesh Chelvanambi, Matthias A Clauss, Dongfang Zhang, Roberto F Machado, Mingqi Gao and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Desheng WangDepartment of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Marta T GomesDivision of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Department of Medicine, Indiana University, Indianapolis, IN 46202, USA.
Yanfei MoDepartment of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Clare C ProhaskaDivision of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Department of Medicine, Indiana University, Indianapolis, IN 46202, USA.
Lu ZhangDepartment of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Sarvesh ChelvanambiDivision of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Department of Medicine, Indiana University, Indianapolis, IN 46202, USA.
Matthias A ClaussDivision of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Department of Medicine, Indiana University, Indianapolis, IN 46202, USA.
Dongfang ZhangDepartment of Pharmacognosy, School of Pharmacy, China Medical University, Shenyang 110122, China.ORCID 0000-0003-4785-7039
Roberto F MachadoDivision of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Department of Medicine, Indiana University, Indianapolis, IN 46202, USA.
Mingqi GaoDepartment of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Yang BaiDepartment of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.ORCID 0000-0002-4420-4553
China Medical University · CNIndiana University Indianapolis · USBrigham and Women's Hospital · US

Funding

Vascular Targeting Genomic & Genetic Strategies for Acute Chest SyndromeR01HL111656 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI Roberto F. Machado · 2013 to 2026
$7.9M
Role of Sphingolipid Pathways in the Pathobiology of PAHR01HL127342 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MACHADO, ROBERTO F., NATARAJAN, VISWANATHAN · 2016 to 2023
$4.5M
NHLBI NIH HHS R01 HL111656NHLBI NIH HHS R01 HL127342
6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is a pulmonary vascular disease characterized by the progressive elevation of pulmonary arterial pressures. It is becoming increasingly apparent that inflammation contributes to the pathogenesis and progression of PAH. Several viruses are known to cause PAH, such as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), human endogenous retrovirus K(HERV-K), and human immunodeficiency virus (HIV), in part due to acute and chronic inflammation. In this review, we discuss the connections between HERV-K, HIV, SARS-CoV-2, and PAH, to stimulate research regarding new therapeutic options and provide new targets for the treatment of the disease.

Indexed as

COVID-19Endogenous RetrovirusesHIV InfectionsPulmonary Arterial HypertensionFamilial Primary Pulmonary HypertensionHIVHumansInflammationSARS-CoV-2human endogenous retrovirus Khuman immunodeficiency virusinflammationpulmonary arterial hypertensionSARS-CoV-2

Identifiers

PMID37108634
PMCPMC10138839
OpenAlexW4366425568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.